At the Brazilian Center for Research in Energy and Materials in Campinas, a tiny lab on a chip is quietly changing the way scientists test new drugs — without using a single lab animal. The device, built from a tough, see-through silicone called PDMS, grows human cells in three dimensions instead of the usual flat dish, creating miniature tissue models that behave far more like a real living body. For the researchers behind it, that means medicines and materials can be tested with far greater accuracy, and fewer animals need to be involved at all.
The technology is called microfluidics, and its superpower is precise control. On a microscopic scale, the device carefully steers the flow of nutrients, oxygen and test substances, keeping the 3D cell clumps — known as spheroids — alive and healthy. Traditional cell cultures grown on flat surfaces miss many of the signals that real tissues send when they meet a drug or an environmental pollutant. Three-dimensional models don't. That makes the platform a breakthrough for drug development, material safety checks and ecotoxicology, the study of how substances affect entire ecosystems.
What really sets this device apart is its reversible design. Most microfluidic platforms are sealed for good, which means once a test is done, the cells inside are stuck. This one can be gently opened after testing to lift out the intact cell models for a closer look. That lets scientists dig deeper into exactly how a drug or nanomaterial interacts with cells — something rarely possible with existing tools. On top of that, assays can run under continuous flow, mimicking the way nutrients and molecules circulate through the body, so lab results more closely match what would actually happen in a living system.
The study, published in the journal ACS Measurement Science Au, delivered three advances at once: a simple, standardized protocol that any researcher can follow even without microfluidics experience; the ability to recover cell models after testing; and realistic continuous-flow conditions. "We've developed a simple and reproducible protocol that will allow researchers from different fields to use the platform," said Iris Renata Sousa Ribeiro, the study's first author and a postdoctoral researcher at the Brazilian Nanotechnology Laboratory. "Furthermore, the ability to recover the cell models after the assays significantly expands the range of analyses that can be performed."
The team now wants to open the doors. By early next year, they plan to make the platform available as shared infrastructure for researchers from universities, research institutes and companies across Brazil, expanding its use in pharmacology, nanotechnology, materials science, biotechnology and ecotoxicology. "We want researchers from across the country to be able to use this technology to develop more accurate toxicity assays that closely resemble actual conditions in living organisms," Ribeiro said. It's a small device with an outsized promise: more reliable testing, richer science, and a more humane path forward.